View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBioera 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Bioera 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Personal Products 산업 성장률13.59%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Jun 2023최근 과거 실적 업데이트Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €19.8m (up 80% from FY 2020). Net income: €15.3m (up €18.9m from FY 2020). Profit margin: 77% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue.Reported Earnings • Apr 21Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €11.8m (down 62% from FY 2019). Net loss: €7.35m (loss widened 23% from FY 2019).모든 업데이트 보기Recent updatesNew Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€810.5k market cap, or US$845.1k). Minor Risk Shareholders have been diluted in the past year (8.1% increase in shares outstanding).New Risk • Jul 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-€5.2m). Revenue has declined by 40% over the past year. Shareholders have been substantially diluted in the past year (70% increase in shares outstanding). Revenue is less than US$1m (€449k revenue, or US$487k). Market cap is less than US$10m (€1.31m market cap, or US$1.42m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).New Risk • Nov 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (409% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$648k). Market cap is less than US$10m (€276.2k market cap, or US$295.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Jul 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 301% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (301% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$661k). Market cap is less than US$10m (€1.33m market cap, or US$1.45m).Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €19.8m (up 80% from FY 2020). Net income: €15.3m (up €18.9m from FY 2020). Profit margin: 77% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue.Reported Earnings • Apr 21Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €11.8m (down 62% from FY 2019). Net loss: €7.35m (loss widened 23% from FY 2019).Is New 90 Day High Low • Mar 04New 90-day low: €0.25The company is down 12% from its price of €0.28 on 04 December 2020. The Italian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 16% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: €0.26The company is down 31% from its price of €0.37 on 18 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.Is New 90 Day High Low • Nov 19New 90-day low: €0.26The company is down 35% from its price of €0.40 on 20 August 2020. The Italian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period.Is New 90 Day High Low • Oct 27New 90-day low: €0.29The company is down 30% from its price of €0.41 on 29 July 2020. The Italian market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 1.0% over the same period.Is New 90 Day High Low • Oct 06New 90-day low: €0.32The company is down 33% from its price of €0.47 on 08 July 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 3.0% over the same period.매출 및 비용 세부 내역Bioera가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BIT:BIE 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 231-61031 Mar 231-51031 Dec 221-40030 Sep 221-110030 Jun 221-181031 Mar 221-91031 Dec 21101030 Sep 21381030 Jun 215152031 Mar 21862031 Dec 2011-43030 Sep 2014-43030 Jun 2017-43031 Mar 2022-53031 Dec 1927-54030 Sep 1931-54030 Jun 1934-55031 Mar 1937-55031 Dec 1840-46030 Sep 1841-46030 Jun 1843-56031 Mar 1845-56031 Dec 1746-57030 Sep 1747-47030 Jun 1749-48031 Mar 1751-38031 Dec 1653-38030 Sep 1655-38030 Jun 1657-38031 Mar 1657-38031 Dec 1557-39030 Sep 1556-39030 Jun 1555-39031 Mar 1554-38031 Dec 1452-28030 Sep 1450-17030 Jun 1449070양질의 수익: BIE가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 BIE의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 BIE의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: BIE의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: BIE의 지난 해 수익 증가율이 Personal Products 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: BIE는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHousehold 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/04/29 04:23종가2025/04/22 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bioera S.p.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €19.8m (up 80% from FY 2020). Net income: €15.3m (up €18.9m from FY 2020). Profit margin: 77% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue.
Reported Earnings • Apr 21Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €11.8m (down 62% from FY 2019). Net loss: €7.35m (loss widened 23% from FY 2019).
New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (€810.5k market cap, or US$845.1k). Minor Risk Shareholders have been diluted in the past year (8.1% increase in shares outstanding).
New Risk • Jul 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-€5.2m). Revenue has declined by 40% over the past year. Shareholders have been substantially diluted in the past year (70% increase in shares outstanding). Revenue is less than US$1m (€449k revenue, or US$487k). Market cap is less than US$10m (€1.31m market cap, or US$1.42m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
New Risk • Nov 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (409% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$648k). Market cap is less than US$10m (€276.2k market cap, or US$295.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Jul 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 301% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (301% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$661k). Market cap is less than US$10m (€1.33m market cap, or US$1.45m).
Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €19.8m (up 80% from FY 2020). Net income: €15.3m (up €18.9m from FY 2020). Profit margin: 77% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue.
Reported Earnings • Apr 21Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €11.8m (down 62% from FY 2019). Net loss: €7.35m (loss widened 23% from FY 2019).
Is New 90 Day High Low • Mar 04New 90-day low: €0.25The company is down 12% from its price of €0.28 on 04 December 2020. The Italian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 16% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: €0.26The company is down 31% from its price of €0.37 on 18 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Nov 19New 90-day low: €0.26The company is down 35% from its price of €0.40 on 20 August 2020. The Italian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Oct 27New 90-day low: €0.29The company is down 30% from its price of €0.41 on 29 July 2020. The Italian market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Oct 06New 90-day low: €0.32The company is down 33% from its price of €0.47 on 08 July 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 3.0% over the same period.